

2019 MID-ATLANTIC
CONFERENCE

9th ANNUAL CURRENT CONCEPTS IN
VASCULAR THERAPIES

2019



Manuela Schuksz
MD PhD

Sentara Vascular
Specialists

May 3rd, 2019


Supervised Exercise Therapy for Claudication



Peripheral Arterial Disease





Asymptomatic




Definition of Claudication

- Pain – most commonly in calves – with ambulation which resolves with rest
- Disease progression:
 - decreased distance
 - increased frequency




Patterns of Disease

- Usually single level of occlusion
-> symptoms in muscle group below site of occlusion
- Distal flow through collaterals
- 3 major patterns:
 - 1) inflow disease
 - 2) outflow disease
 - 3) combined disease



Natural History

- Slow progression to shorter walking distances
- Rarely limb threatening
- 5yr rate of amputation: <5%
- Clinical deterioration: 25%
- **BUT:**
 - 1) profound impact on quality of life
 - 2) high risk of death – marker for systemic atherosclerosis
 - 42%, 65% mortality at 5, 10yrs
 - 66% due to MI




Treatment Approach

- **Risk Factor Identification and Modification**
 - ASA for MI/CVA prevention
 - smoking cessation (delays progression, decreases risk of death, decreases graft failure rates)
 - tight glucose control
 - normotension (ACE inhibitor)
 - statin (stabilize existing plaque, reduce vascular inflammation)
- **Pharmacological Therapy**
 - cilostazol
- **Structured Exercise Therapy**
- **Endovascular or Surgical Intervention**



Treatment for Claudication

- **MEDICAL FIRST!**
 - Risk of CV event >> risk of limb loss
- Intervention is reserved for
 - Severe, non-remitting, life style-limiting disease



Exercise Therapy for Claudication

- Benefits of exercise in claudicants have been recognized for 30 years

Benefit of Exercise Conditioning for Patients With Peripheral Arterial Disease

William F **Exercise Rehabilitation Programs for the Treatment of Claudication Pain**
A Meta-analysis

Andrew W. Gardner, PhD

JAMA. 1995;274(12):975-981

Exercise Training for Claudication

Kerry J. Stewart, Ed.D., William R. Hiatt, M.D., Judith G. Regensteiner, Ph.D., and Alan T. Hirsch, M.D.

December 12, 2002

N Engl J Med 2002;347:1941-1951



Benefits of supervised exercise therapy

- Reduced cardiovascular risk, decreased XOL, SBP and improved glycemic control
- Improved maximal treadmill walking distance
 - By approx. 200m
- Improved pain-free walking distance
 - By approx. 130m
- Improved 6 min walk test
- Improved QoL scores
- Greater benefit to older patients
- Supervised seems to be superior

Selected References:

Hageman et al, Cochrane review. 2018

Gardner et al, JAMA. 1995

Stewart et al, N Engl J Med. 2002

Vemulapalli et al, Am Heart J. 2015

Wind et al, Eur J Vasc Endovasc Surg. 2007




Key Components of a Structured Exercise Program

- 30-60 min of supervised exercise, at least 3x/week for at least 12 weeks
- Treadmill or track walking
- Walk to point of moderate pain before rest
- Program should have complementary educational components
- Administered by an individual trained in exercise therapy



Challenges of supervised exercise therapy

- Patient compliance
- Requires commitment
- ***No insurance coverage until recently***



Decision Memo for Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD) (CAG-00449N)

Decision Summary

- A. The Centers for Medicare & Medicaid Services (CMS) has determined that the evidence is sufficient to cover supervised exercise therapy (SET) for beneficiaries with intermittent claudication (IC) for the treatment of symptomatic peripheral artery disease (PAD). Up to 36 sessions over a 12 week period are covered if all of the following components of a SET program are met:

The SET program must:

- o consist of sessions lasting 30-60 minutes comprising a therapeutic exercise-training program for PAD in patients with claudication;
- o be conducted in a hospital outpatient setting, or a physician's office;
- o be delivered by qualified auxiliary personnel necessary to ensure benefits exceed harms, and who are trained in exercise therapy for PAD; and
- o be under the direct supervision of a physician (as defined in 1861(r)(1)), physician assistant, or nurse practitioner/clinical nurse specialist (as identified in 1861(aa)(5)) who must be trained in both basic and advanced life support techniques.

Beneficiaries must have a face-to-face visit with the physician responsible for PAD treatment to obtain the referral for SET. At this visit, the beneficiary must receive information regarding cardiovascular disease and PAD risk factor reduction, which could include education, counseling, behavioral interventions, and outcome assessments.

- B. Medicare Administrative Contractors (MACs) have the discretion to cover SET beyond 36 sessions over 12 weeks and may cover an additional 36 sessions over an extended period of time. A second referral is required for these additional sessions.
- C. SET is non-covered for beneficiaries with absolute contraindications to exercise as determined by their primary physician.

May 25, 2017



Treatment Approach

- **Risk Factor Identification and Modification**
 - ASA for MI/CVA prevention
 - smoking cessation (delays progression, decreases risk of death, decreases graft failure rates)
 - tight glucose control
 - normotension (ACE inhibitor)
 - statin (stabilize existing plaque, reduce vascular inflammation)
- **Pharmacological Therapy**
 - cilostazol
- **Structured Exercise Therapy – can now actually be prescribed**
- **Endovascular or Surgical Intervention**



Intervention for Claudication

- Has remained controversial
- Traditional teaching has been risk factor modification and exercise
“stop smoking and keep walking”
- Surgical intervention reserved for severe symptoms -
“life-style limiting” – in low risk patients
- Advent of endovascular therapies has led to more liberal indications

But are we serving this patient population by increasing intervention rate?



Supervised Exercise, Stent Revascularization, or Medical Therapy for Claudication Due to Aortoiliac Peripheral Artery Disease


The CLEVER Study

Timothy P. Murphy, MD,* Donald E. Cutlip, MD,†† Judith G. Regensteiner, PhD,§ Emile R. Mohler III, MD,||
David J. Cohen, MD, MSc,¶ Matthew R. Reynolds, MD,‡ Joseph M. Massaro, PhD,‡# Beth A. Lewis, PhD,**
Joselyn Cerezo, MD,* Niki C. Oldenburg, DrPH,†† Claudia C. Thum, MA,‡ Michael R. Jaff, DO,‡†
Anthony J. Comerota, MD,§§ Michael W. Steffes, MD,†† Ingrid H. Abrahamsen, MS,‡ Suzanne Goldberg, MSN,
Alan T. Hirsch, MD†† (J Am Coll Cardiol 2015;65:999-1009)

- Prospective, multicenter, randomized, controlled, comparative effectiveness trial
- 111 patients with IC due to aorto-iliac disease
 - Supervised exercise
 - Primary stenting
 - Optimal medical management (cilostazol)
- 6 months and 18 months outcomes
- Outcome measures
 - Peak walking time
 - Claudication onset time
 - Quality of Life measures



CENTRAL ILLUSTRATION Exercise or Intervention for Claudication Due to Aortoiliac PAD: PWT and COT




Peak walking time

SET is

- superior to endovascular intervention for peak walking time
- equivalent for claudication onset time

Claudication onset time



Murphy, T.P. et al. J Am Coll Cardiol. 2015; 65(10):999-1009.

(Upper panel) PWT. Patients with 18-month follow-up visit only. **(Lower panel)** COT. COT = claudication onset time on a graded treadmill test; PAD = peripheral artery disease; PWT = peak walking time on a graded treadmill test.

Pivotal study in obtaining CMS coverage for SET



Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication

Meta-Analysis of Randomized Controlled Trials

Ambarish Pandey, MD,^a Subhash Banerjee, MD,^a Christian Ngo, MD,^a Purav Mody, MD,^a Steven P. Marso, MD,^a Emmanouil S. Brilakis, MD, PhD,^a Ehrin J. Armstrong, MD, MS,^b Jay Giri, MD, MPH,^c Marc P. Bonaca, MD, MPH,^d Aruna Pradhan, MD, MPH,^d Anthony A. Bavry, MD, MPH,^e Dharam J. Kumbhani, MD, SM^a




JACC: CARDIOVASCULAR INTERVENTIONS VOL. 10, NO. 7, 2017
APRIL 10, 2017:712-24

- Meta-analysis assessing endovascular revascularization with or without SET
- 7 trials, 987 patients. Aortoiliac and femoropopliteal Dz
- Outcome Measures:
 - max treadmill walking distance at 12 months
 - Need for revascularization or amputation at follow up




- Results:
 - Maximal walking distance SET vs. endo only

FIGURE 2 Forest Plot for Maximal Walking Distance on Follow-Up




- Results:
 - Maximal walking distance SET vs. SET + endo




- Results:
 - Need for revascularization or amputation at f/u SET vs. endo only

FIGURE 4 Forest Plot for Need for Revascularization or Amputation on Follow-Up



- Results:
 - Need for revascularization or amputation at f/u SET vs. SET + endo



Summary

- No benefit to endovascular intervention alone compared to SET
 - maximal walking distance
 - Need for repeat intervention/amputation
- There IS a potentiating effect of combined endovascular intervention AND exercise
 - Improvement in all outcome measures



In Conclusion:

Vascular Rehab is indeed for Real!

- SET has been known to provide benefits to claudicants for 3 decades
 - Increased maximal and pain free walking distance
 - Improved quality of life assessment
 - Recommended first line therapy for claudication
- Now covered by Medicare – 2018!
 - 3rd party payers pending
- Ability to use endovascular treatment in conjunction with SET may further improve patient outcome
 - Further studies needed
 - Aortoiliac vs. femoropopliteal interventions
 - Longer term outcomes



*Thank you for your
attention*

